News
Kamada says first year of inhaled Alpha-1 augmentation trial shows excellent safety, tolerability
Business Wire
NESS ZIONA, Israel — Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced the interim report of its phase 2-3 trial to treat Alpha-1 Antitrypsin Deficiency with its flagship product delivered by inhalation.
The report, which includes information on 13 months treatment of dozens of patients, shows an excellent safety and tolerability profile. The report adds significant further information to the safety profile of Kamada’s inhaled Alpha-1 Antitrypsin that has already been established in five previous clinical trials.
The current Phase 2-3 trial is the most advanced stage a company has ever reached with inhaled augmentation therapy. The trial is performed at several sites in Europe, including Germany, the United Kingdom, the Netherlands, Denmark, Ireland and Scotland.
The report allows Kamada to use the data collected in additional regulatory submissions and provides physicians and regulatory authorities additional confidence in the Kamada drug.
